First-Line Chemotherapy With Liposomal Doxorubicin Plus Cyclofosfamide In Metastatic Breast Cancer: A Case Report Of Early And Prolonged Response
INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY(2013)
Abstract
The treatment choice for metastatic breast cancer should consider the appropriate balance between efficacy and toxicity of the therapy. We discuss a clinical case with an early response and prolonged to liposomal anthracyclines-based chemotherapy, without cardiotoxicity, enhancing the evidence of safety of liposomal formulation to prevent heart damage. Moreover, the case seems to be of interest for the role of F-18-FDG-PET in clinical response assessment: an early decrease of the standardized uptake value value, even before conventional imaging evaluation, is highly predictive for prolonged clinical response.
MoreTranslated text
Key words
first-line chemotherapy, metastatic breast cancer, non-pegylated liposomal doxorubicin, positron emission tomography
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined